Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

A blood-based proteomic classifier for the molecular characterization of pulmonary nodules.

Li XJ, Hayward C, Fong PY, Dominguez M, Hunsucker SW, Lee LW, McLean M, Law S, Butler H, Schirm M, Gingras O, Lamontagne J, Allard R, Chelsky D, Price ND, Lam S, Massion PP, Pass H, Rom WN, Vachani A, Fang KC, Hood L, Kearney P.

Sci Transl Med. 2013 Oct 16;5(207):207ra142. doi: 10.1126/scitranslmed.3007013.

2.

Validation of a multiprotein plasma classifier to identify benign lung nodules.

Vachani A, Pass HI, Rom WN, Midthun DE, Edell ES, Laviolette M, Li XJ, Fong PY, Hunsucker SW, Hayward C, Mazzone PJ, Madtes DK, Miller YE, Walker MG, Shi J, Kearney P, Fang KC, Massion PP.

J Thorac Oncol. 2015 Apr;10(4):629-37. doi: 10.1097/JTO.0000000000000447.

3.

Assessment of Plasma Proteomics Biomarker's Ability to Distinguish Benign From Malignant Lung Nodules: Results of the PANOPTIC (Pulmonary Nodule Plasma Proteomic Classifier) Trial.

Silvestri GA, Tanner NT, Kearney P, Vachani A, Massion PP, Porter A, Springmeyer SC, Fang KC, Midthun D, Mazzone PJ; PANOPTIC Trial Team.

Chest. 2018 Sep;154(3):491-500. doi: 10.1016/j.chest.2018.02.012. Epub 2018 Mar 1.

4.

Clinical Utility of a Plasma Protein Classifier for Indeterminate Lung Nodules.

Vachani A, Hammoud Z, Springmeyer S, Cohen N, Nguyen D, Williamson C, Starnes S, Hunsucker S, Law S, Li XJ, Porter A, Kearney P.

Lung. 2015 Dec;193(6):1023-7. doi: 10.1007/s00408-015-9800-0. Epub 2015 Sep 16.

5.

Development and validation of a plasma biomarker panel for discerning clinical significance of indeterminate pulmonary nodules.

Daly S, Rinewalt D, Fhied C, Basu S, Mahon B, Liptay MJ, Hong E, Chmielewski G, Yoder MA, Shah PN, Edell ES, Maldonado F, Bungum AO, Borgia JA.

J Thorac Oncol. 2013 Jan;8(1):31-6. doi: 10.1097/JTO.0b013e31827627f8.

6.

A classifier integrating plasma biomarkers and radiological characteristics for distinguishing malignant from benign pulmonary nodules.

Lin Y, Leng Q, Jiang Z, Guarnera MA, Zhou Y, Chen X, Wang H, Zhou W, Cai L, Fang H, Li J, Jin H, Wang L, Yi S, Lu W, Evers D, Fowle CB, Su Y, Jiang F.

Int J Cancer. 2017 Sep 15;141(6):1240-1248. doi: 10.1002/ijc.30822. Epub 2017 Jun 21.

7.

A Gene Expression Classifier from Whole Blood Distinguishes Benign from Malignant Lung Nodules Detected by Low-Dose CT.

Kossenkov AV, Qureshi R, Dawany NB, Wickramasinghe J, Liu Q, Majumdar RS, Chang C, Widura S, Kumar T, Horng WH, Konnisto E, Criner G, Tsay JJ, Pass H, Yendamuri S, Vachani A, Bauer T, Nam B, Rom WN, Showe MK, Showe LC.

Cancer Res. 2019 Jan 1;79(1):263-273. doi: 10.1158/0008-5472.CAN-18-2032. Epub 2018 Nov 28.

8.

Diagnosis of lung cancer in individuals with solitary pulmonary nodules by plasma microRNA biomarkers.

Shen J, Liu Z, Todd NW, Zhang H, Liao J, Yu L, Guarnera MA, Li R, Cai L, Zhan M, Jiang F.

BMC Cancer. 2011 Aug 24;11:374. doi: 10.1186/1471-2407-11-374.

9.

Identification of Proteomic Features To Distinguish Benign Pulmonary Nodules from Lung Adenocarcinoma.

Codreanu SG, Hoeksema MD, Slebos RJC, Zimmerman LJ, Rahman SMJ, Li M, Chen SC, Chen H, Eisenberg R, Liebler DC, Massion PP.

J Proteome Res. 2017 Sep 1;16(9):3266-3276. doi: 10.1021/acs.jproteome.7b00245. Epub 2017 Aug 8.

10.

Added value of a serum proteomic signature in the diagnostic evaluation of lung nodules.

Pecot CV, Li M, Zhang XJ, Rajanbabu R, Calitri C, Bungum A, Jett JR, Putnam JB, Callaway-Lane C, Deppen S, Grogan EL, Carbone DP, Worrell JA, Moons KG, Shyr Y, Massion PP.

Cancer Epidemiol Biomarkers Prev. 2012 May;21(5):786-92. doi: 10.1158/1055-9965.EPI-11-0932. Epub 2012 Feb 28.

11.

Automated lung nodule classification following automated nodule detection on CT: a serial approach.

Armato SG 3rd, Altman MB, Wilkie J, Sone S, Li F, Doi K, Roy AS.

Med Phys. 2003 Jun;30(6):1188-97.

PMID:
12852543
12.

Biomarkers to help guide management of patients with pulmonary nodules.

Patz EF Jr, Campa MJ, Gottlin EB, Trotter PR, Herndon JE 2nd, Kafader D, Grant RP, Eisenberg M.

Am J Respir Crit Care Med. 2013 Aug 15;188(4):461-5. doi: 10.1164/rccm.201210-1760OC.

PMID:
23306547
13.

Serum phosphatidylethanolamine levels distinguish benign from malignant solitary pulmonary nodules and represent a potential diagnostic biomarker for lung cancer.

Fahrmann JF, Grapov D, DeFelice BC, Taylor S, Kim K, Kelly K, Wikoff WR, Pass H, Rom WN, Fiehn O, Miyamoto S.

Cancer Biomark. 2016 Mar 11;16(4):609-17. doi: 10.3233/CBM-160602.

14.

Angiogenesis Biomarkers May Be Useful in the Management of Patients With Indeterminate Pulmonary Nodules.

Seder CW, Kubasiak JC, Pithadia R, Basu S, Fhied C, Tarhoni I, Davila E, Alnajjar H, Chmielewski GW, Warren WH, Liptay MJ, Borgia JA.

Ann Thorac Surg. 2015 Aug;100(2):429-36. doi: 10.1016/j.athoracsur.2015.04.018. Epub 2015 Jun 30. Erratum in: Ann Thorac Surg. 2019 Nov;108(5):1588.

PMID:
26138771
15.

[Serum proteomic patterns may assist the diagnosis of solitary pulmonary nodules].

Luo XY, Chen HQ, Sun YH, Zhou JH, Wang WF, Liao P, Xiang CQ.

Zhonghua Zhong Liu Za Zhi. 2006 Dec;28(12):907-10. Chinese.

PMID:
17533741
16.

Comparative Study of Autoantibody Responses between Lung Adenocarcinoma and Benign Pulmonary Nodules.

Wang J, Shivakumar S, Barker K, Tang Y, Wallstrom G, Park JG, Tsay JC, Pass HI, Rom WN, LaBaer J, Qiu J.

J Thorac Oncol. 2016 Mar;11(3):334-45. doi: 10.1016/j.jtho.2015.11.011. Epub 2016 Feb 16.

17.

Computer-aided diagnosis of pulmonary nodules using a two-step approach for feature selection and classifier ensemble construction.

Lee MC, Boroczky L, Sungur-Stasik K, Cann AD, Borczuk AC, Kawut SM, Powell CA.

Artif Intell Med. 2010 Sep;50(1):43-53. doi: 10.1016/j.artmed.2010.04.011. Epub 2010 May 31.

PMID:
20570118
18.

A visual and semi-quantitative assessment of (99m)Tc-EDDA/HYNIC-TOC scintigraphy in differentiation of solitary pulmonary nodules.

Płachcińska A, Mikołajczak R, Kozak J, Rzeszutek K, Kuśmierek J.

Nucl Med Rev Cent East Eur. 2004;7(2):143-50.

PMID:
15968601
19.

Value of folate receptor-positive circulating tumour cells in the clinical management of indeterminate lung nodules: A non-invasive biomarker for predicting malignancy and tumour invasiveness.

Zhou Q, Geng Q, Wang L, Huang J, Liao M, Li Y, Ding Z, Yang S, Zhao H, Shen Q, Pan C, Lou J, Lu S, Chen C, Luo Q.

EBioMedicine. 2019 Mar;41:236-243. doi: 10.1016/j.ebiom.2019.02.028. Epub 2019 Mar 12.

Supplemental Content

Support Center